Emphascience
Emphascience, Inc. is a private pharmaceutical company focused on developing novel formulations of proven drug products to address unmet medical needs in the treatment of pain, cancer, infections, and many fatal and debilitating diseases. They aim to redesign existing medicines to improve properties, expand scope, and offer faster, safer, and more effective therapeutic options with minimal clinical studies and patent protection. Their culture emphasizes science, creativity, and practical solutions to drug formulation challenges.
Industries
Nr. of Employees
small (1-50)
Emphascience
Pittsford, New York, United States, North America
Products
Oral formulation of a poorly water-soluble drug currently delivered by intramuscular depot
Prototype work to enable oral administration of a drug currently available only as a long-acting intramuscular depot by improving oral bioavailability and shelf-life.
Stable injectable formulation avoiding allergenic excipients
Development of a sterile injectable formulation stabilized without commonly used allergenic excipients (example: formulations without sulfites) to enable safer storage and extended usability.
Combination formulations to reduce opioid exposure
Formulation concepts combining non-opioid analgesics with reduced opioid doses to maintain pain control while aiming to reduce opioid-related adverse effects and abuse potential.
Long-acting intramuscular serotonin receptor modulator depot
Prototype long-acting intramuscular depot formulation of a serotonin-receptor-targeting agent intended to provide single-injection management of acute and delayed-onset symptoms (e.g., nausea).
Oral formulation of a poorly water-soluble drug currently delivered by intramuscular depot
Prototype work to enable oral administration of a drug currently available only as a long-acting intramuscular depot by improving oral bioavailability and shelf-life.
Stable injectable formulation avoiding allergenic excipients
Development of a sterile injectable formulation stabilized without commonly used allergenic excipients (example: formulations without sulfites) to enable safer storage and extended usability.
Combination formulations to reduce opioid exposure
Formulation concepts combining non-opioid analgesics with reduced opioid doses to maintain pain control while aiming to reduce opioid-related adverse effects and abuse potential.
Long-acting intramuscular serotonin receptor modulator depot
Prototype long-acting intramuscular depot formulation of a serotonin-receptor-targeting agent intended to provide single-injection management of acute and delayed-onset symptoms (e.g., nausea).
Services
Formulation development services
Development of new or improved formulations for approved drug molecules, including oral, injectable, and topical dosage forms.
Prototype concept development
Early-stage design and prototyping of reformulated product concepts to de-risk and prepare for partner-led clinical proof-of-concept.
Partnering and out-licensing
Out-licensing of reformulated products and collaboration with partners for clinical development and commercialization.
Formulation development services
Development of new or improved formulations for approved drug molecules, including oral, injectable, and topical dosage forms.
Prototype concept development
Early-stage design and prototyping of reformulated product concepts to de-risk and prepare for partner-led clinical proof-of-concept.
Partnering and out-licensing
Out-licensing of reformulated products and collaboration with partners for clinical development and commercialization.
Expertise Areas
- Formulation development across dosage forms (oral, injectable, topical)
- Injectable drug development and sterilization
- Solubility and bioavailability enhancement
- Sustained-release and depot formulations
Key Technologies
- Solubility enhancement technologies
- Extended-release depot injection platforms
- Terminal sterilization for injectables
- Excipient selection and alternative stabilization strategies